Has (NASDAQ: MRNA) finally bottomed out? You may be asking that yourself right now, as shares in the biotech company have held steady at around $25 per share over the past six months.

Moderna might be a shell of its former self, no longer making billions from its COVID-19 vaccine, but it's still sitting on billions of dollars in capital. The company also has many promising candidates in its drug development pipeline.

Image source: Getty Images.

Continue reading

Source Fool.com